OTHER INFORMATION
+Added: None of our directors or officers have ado pted , modified, or termi nated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended March 31, 2024.
The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report.
Description of Exhibit
−Removed: Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1 (No.
−Removed: 333-256516) filed with the SEC on May 27, 2021).
−Removed: Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 20, 2023).
+Added: Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2024).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Acurx Pharmaceuticals, Inc.
−Removed: November 13, 2023
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 13, 2023
/s/ Robert G.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.